The economic burden of allergic rhinitis: A critical evaluation of the literature

PharmacoEconomics

Volumn 22, Issue 6, 2004, Pages 345-361

  Reed, Shelby D ^a,d   Lee, Todd A ^b,c   McCrory, Douglas C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b HINES VA HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; BUDESONIDE; CHLORPHENIRAMINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DECONGESTIVE AGENT; FLUTICASONE; IPRATROPIUM BROMIDE; MOMETASONE FUROATE; PROPIONIC ACID; PSEUDOEPHEDRINE; TERFENADINE;

ALLERGIC RHINITIS; AVOIDANCE BEHAVIOR; CLINICAL TRIAL; COGNITIVE DEFECT; CONFIDENCE INTERVAL; CONSTIPATION; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; ECONOMIC EVALUATION; ENVIRONMENTAL EXPOSURE; HEALTH CARE MANAGEMENT; HUMAN; IMMUNOTHERAPY; MEDICAL LITERATURE; MENTAL INSTABILITY; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; VERTIGO; VISUAL IMPAIRMENT; XEROSTOMIA;

ANTI-ALLERGIC AGENTS; COST OF ILLNESS; ECONOMICS, PHARMACEUTICAL; HISTAMINE H1 ANTAGONISTS; HUMANS; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL; UNITED STATES;

EID: 2342605527     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422060-00002     Document Type: Review

References (73)

1. Bellanti JA, Wallerstedt DB. Allergic rhinitis update: epidemiology and natural history. Allergy Asthma Proc 2000; 21: 367-70
2. Sly RM. Changing prevalence of allergic rhinitis and asthma. Ann Allergy Asthma Immunol 1999; 82: 233-48
3. Schoenwetter WF. Allergic rhinitis: epidemiology and natural history. Allergy Asthma Proc 2000; 21: 1-6
4. Kalyoncu AF, Demir AU, Ozcakar B, et al. Asthma and allergy in Turkish university students: two cross-sectional surveys 5 years apart. Allergol Immunopathol (Madr) 2001; 29: 264-71
5. Linneberg A, Nielsen NH, Madsen F, et al. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart: the Copenhagen Allergy Study. J Allergy Clin Immunol 2000; 106: 247-52
6. McMenamin P. Costs of hay fever in the United States in 1990. Ann Allergy 1994; 73: 35-9
7. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99: 22-7
8. Mackowiak JI. The health and economic impact of rhinitis. Am J Manag Care 1997; 3: S8-S18
9. Baraniuk JM, Meltzer EO, Spector SL. Impact of allergic rhinitis and related airway disorders. J Respir Dis 1996; 17 Suppl.: 511-23
10. Storms W, Meltzer EO, Nathan RA, et al. The economic impact of allergic rhinitis. J Allergy Clin Immunol 1997; 99: S820-4
11. Ray NF, Baraniuk JN, Thamer M, et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol 1999; 103: 401-7
12. Law AW, Reed SD, Sundy J, et al. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol 2003; 111: 296-300
13. Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997; 99: S742-9
14. Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol 2002; 88: 2-7
15. Blanc PD, Trupin L, Eisner M, et al. The work impact of asthma and rhinitis: findings from a population-based survey. J Clin Epidemlol 2001; 54: 610-8
16. Ross RN. The costs of allergic rhinitis. Am J Manag Care 1996; 2: 285-90
17. Crystal-Peters J, Crown WH, Goetzel RZ, et al. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000; 6: 373-8
18. Kessler RC, Almeida DM, Berglund P, et al. Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthama Immunol 2001; 87: 289-95
19. Management of allergic rhinitis in the working-age population. Evidence report/technology assessment: number 67. Rockville (MD): Agency for Healthcare Research and Quality, 2003 Feb. AHRQ Publication No. 03-E013
20. D'Alonzo Jr GE. Scope and impact of allergic rhinitis. J Am Osteopath Assoc 2002; 102 (6 Suppl. 2): S2-6
21. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998; 317: 1624-9
22. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis. Ann Allergy Asthma Immunol 2002; 89: 479-84
23. Nielsen LP, Dahl R. Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis: a review of randomized, controlled trials. Am J Respir Med 2003; 2 (1): 55-65
24. Stempel DA, Thomas M. Treatment of allergic rhinitis: an evidence-based evaluation of nasal corticosteroids versus non-sedating antihistamines. Am J Manag Care 1998; 4: 89-96
25. Management of allergic and nonallergic rhinitis. Evidence report/technology assessment: number 54. Rockville (MD): Agency for Healthcare Research and Quality, 2002 May. AHRQ Publication No. 02-E024
26. Corren J. Intranasal corticosteroids for allergic rhinitis: how do different agents compare? J Allergy Clin Immunol 1999; 104 (4 Pt 1): S144-9
27. Nielsen LP, Mygind N, Dahl R. Intranasal corticosteroids for allergic rhinitis: superior relief? Drugs 2001; 61: 1563-79
28. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000; 106 (4 Suppl.): S179-90
29. Lumry WR. A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol 1999 Oct; 104 (4 Pt 1): S150-8
30. Pedersen S. Assessing the effect of intranasal steroids on growth. J Allergy Clin Immunol 2001; 108 (1 Suppl.): S40-4
31. Szefler SJ. Pharmacokinetics of intranasal corticosteroids. J Allergy Clin Immunol 2001; 108 (1 Suppl.): S26-31
32. Mattila MJ, Paakkari I. Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 1999; 55: 85-93
33. Bradley CM, Nicholson AN. Studies on the central effects of the H1-antagonist, loratadine. Eur J Clin Pharmacol 1987; 32: 419-21
34. Hindmarch I, Shamsi Z. The effects of single and repeated administration of ebastine on cognition and psychomotor performance in comparison to triprolidine and placebo in healthy volunteers. Curr Med Res Opin 2001; 17 (4): 273-81
35. Kerr JS, Dunmore C, Hindmarch I. The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, triprolidine and placebo in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 331-5
36. Simons FE, Fraser TG, Reggin JD, et al. Comparison of the central nervous system effects produced by six H1-receptor antagonists. Clin Exp Allergy 1996; 26: 1092-7
37. Shamsi Z, Kimber S, Hindmarch I. An investigation into the effects of cetirizine on cognitive function and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol 2001; 56: 865-71
38. Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999; 48: 200-6
39. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89: 479-84
40. Schramm B, Ehlken B, Smala A, et al. Cost of illness of atopic asthma and seasonal allergic rhinitis in Germany: 1-year retrospective study. Eur Respir J 2003; 21: 116-22
41. Trotter JP. The treatment of seasonal allergic rhinitis: cost implications of pharmacotherapy for managed care. Manag Care Interface 2000; 13: 60-2
42. Liao E, Leahy M, Cummins G. The costs of nonsedating antihistamine therapy for allergic rhinitis in managed care: an updated analysis. Am J Manag Care 2001; 7: S459-68
43. Lee J, Cummins G, Okamoto L. A descriptive analysis of the use and cost of new-generation antihistamines in the treatment of allergic rhinitis: a retrospective database analysis. Am J Manag Care 2001; 7 (4 Suppl.): S103-12
44. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81 (5 Pt 2): 478-518
45. Wang DY, Nid M, Smith JD, et al. Rhinitis: do diagnostic criteria affect the prevalence and treatment? Allergy 2002; 57: 150-4
46. Carvalho N, Fernandez-Benitez M, Cascante L, et al. International study of asthma and allergies in childhood: results on rhinitis of first phase in Pamplona, Spain. Allergol Immunopathol (Madr) 2000; 28: 207-12
47. Asher MI, Barry D, Clayton T, et al. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase One. The burden of symptoms of asthma, allergic rhinoconjunctivities and atopic eczema in children and adolescents in six New Zealand centres: ISAAC Phase One. N Z Med J 2001; 114: 114-20
48. Vanna AT, Yamada E, Arruda LK, et al. International Study of Asthma and Allergies in Childhood: validation of the rhinitis symptom questionnaire and prevalence of rhinitis in schoolchildren in Sao Paulo, Brazil. Pediatr Allergy Immunol 2001; 12: 95-101
49. Akcakaya N, Kulak K, Hassanzadeh A, et al. Prevalence of bronchial asthma and allergic rhinitis in Istanbul school children. Eur J Epidemlol 2000; 16: 693-9
50. Yawn BP, Yunginger JW, Wollan PC, et al. Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. J Allergy Clin Immunol 1999; 103: 54-9
51. Ward MM, Javitz HS, Smith WM, et al. Lost income and work limitations in persons with chronic respiratory disorders. J Clin Epidemiol 2002; 55: 260-8
52. Tanner LA, Reilly M, Meltzer EO, et al. Effect of fexofenadine HCl on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Manag Care 1999; 5: S235-47
53. Crown WH. Productivity measurement in pharmaceutical studies. Drug Benefit Trends 2000; 12: 5BH-8BH
54. Greenberg PE, Birnbaum HG, Kessler RC, et al. Impact of illness and its treatment on workplace costs: regulatory and measurement issues. J Occup Environ Med 2001; 43: 56-63
55. The Gallup Organization Inc. Survey of attitudes and experiences of allergy sufferers. Washington, DC: The Gallup Organization Inc., 1989 Dec
56. Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clin Drug Invest 1996; 11: 278-88
57. Meltzer EO, Casale TB, Nathan RA, et al. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment In patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999; 83: 311-7
58. Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104: 100-6
59. Pransky G, Finkelstein SN, Berndt E, et al. Measuring health impacts on work performance: comparing subjective and objective reports [abstract]. Value Health 2002; 5: 448-9
60. Cockburn IM, Bailit HL, Berndt ER, et al. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41: 948-53
61. Burton WN, Conti DJ, Chen CY, et al. The impact of allergies and allergy treatment on worker productivity. J Occup Environ Med 2001; 43: 64-71
62. Leickly FE, Sears-Ewald D, Ownby DR. A comperative cost-effectiveness study of two treatment modalities for ragweed hay fever. Am J Rhinol 1989; 3: 99-104
63. Kozma CM, Schulz RM, Sclar DA, et al. A comparison of costs and efficacy of intranasal fluticasone propionate and terfenadine tablets for seasonal allergic rhinitis. Clin Ther 1996; 18: 334-46
64. Keith PK, Haddon J, Birch S. A cost-benefit analysis using a willingness-to-pay questionnaire of intranasal budesonide for seasonal allergic rhinitis: Rhinocort Study Group. Ann Allergy Asthama Immunol 2000; 84: 55-62
65. Schädlich PK, Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17 (1): 37-52
66. Stahl E, van Rompay W, Wang EC, et al. Cost-effectiveness analysis of budesonide aqueous nasal spray and fluticasone propionate nasal spray in the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 2000; 84: 397-402
67. Donahue JG, Greineder DK, Connor-Lacke L, et al. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol 1999; 82: 339-47
68. Sullivan SD, Weiss KB. Health economics of asthma and rhinitis: II. Assessing the value of interventions. J Allergy Clin Immunol 2001; 107: 203-10
69. Juniper EF, Thompson AK, Ferrie PJ, et al. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol 1999; 104: 364-9
70. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21: 77-83
71. Juniper EF, Guyatt GH, Griffith LE, et al. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol 1996; 98: 843-5
72. de Graaf-in't Veld T, Koenders S, Garrelds IM, et al. The relationships between nasal hyperreactivity, quality of life, and nasal symptoms in patients with perennial allergic rhinitis. J Allergy Clin Immunol 1996; 98: 508-13
73. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index. Qual Life Res 1998; 7: 693-702